The findings were published Feb. 24 in Nature Communications. In the trial’s second phase, 30 patients were divided into two cohorts and received different drug combinations before undergoing therapeutic lymph node dissection surgery.
One cohort was treated with a combination of vemurafenib, cobimetinib and atezolizumab. The other was treated with the cobimetinib and atezolizumab combination only. Both cohorts received atezolizumab after surgery.
Treatment resulted in complete or almost complete elimination of tumors for 50% of trial participants across both cohorts. Additionally, tumors were significantly shrunk for 20% of participants in both cohorts.
Researchers identified the small sample size and academic setting as possible limitations to generalizing the trial’s findings.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
